

ASX ANNOUNCEMENT

30 July 2024

CLEANSING NOTICE UNDER SECTION 708A(5)(e)

On 30 July 2024, Anteris Technologies Ltd (ASX: AVR) (**Anteris** or the **Company**) issued:

- 1,875,000 new fully paid ordinary shares (**New Shares**) were issued to various institutional and sophisticated investors at an issue price of \$16.00 per new share, raising \$30,000,000 before issue costs.
- 41,000 new fully paid ordinary shares (**New Shares**) were issued to Evolution Capital Pty Ltd as partial payment of their fees for services performed, amounting to \$656,000, representing 41,000 shares at an issue price of \$16.00 per new share.

Details of the securities issued

Class of securities: Fully paid ordinary shares

ASX code: AVR

Dates of the issues: 30 July 2024

Total number of securities issued: 1,916,000

Anteris gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (the **Corporations Act**) that:

1. the New Shares have been issued without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of this notice, the Company has complied with:
 - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (b) section 674 and 674A of the Corporations Act;
3. as at the date of this notice, there is no 'excluded information' of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by Anteris under section 708A(6)(e) of the Corporations Act.

ENDS



About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering transformative solutions to structural heart disease patients.

The Company's lead product, DurAVR[®], is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR[®] THV was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

DurAVR[®] THV is made using ADAPT[®] tissue, Anteris' patented anti-calcification tissue technology. ADAPT[®] tissue has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.

The ComASUR[®] Delivery System was designed to provide controlled deployment and accurate placement of the DurAVR[®] THV with balloon-expandable delivery, allowing precise alignment with the heart's native commissures to achieve optimal valve positioning.

Anteris Technologies is set to revolutionise the structural heart market by delivering clinically superior solutions for significant unmet clinical needs.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Investor Relations

investors@anteristech.com
Anteris Technologies Ltd
+61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)

Malini Chatterjee, Ph.D.
Managing Director
Blueprint Life Science Group
+1 917 330 4269

| | |
|----------|---|
| Website | www.anteristech.com |
| Twitter | @AnterisTech |
| Facebook | www.facebook.com/AnterisTechnologies |
| LinkedIn | https://www.linkedin.com/company/anteristech |

